• Somatic preleukemic GATA1s mutations are acquired before birth in 25% of neonates with DS, and are not acquired postnatally.

  • Rates of transformation of GATA1s clones detected at birth are low, but all mutated clones persisting >6 months transformed to ML-DS.

Abstract

Children with Down syndrome (DS) have a high risk of GATA1-associated myeloid leukemia (ML-DS) before age 4 years. Somatic N-terminal GATA1 mutations (GATA1s) are necessary, but not sufficient, for ML-DS, but their significance at birth for individual babies and whether mutations occur after birth is unclear. To address these questions, we performed a prospective study of newborns with DS using next-generation sequencing-based GATA1 mutation analysis, with hematologic and clinical evaluation and follow-up for the window of ML-DS risk. Of 450 neonates with DS, 113 (25%) had GATA1s mutations, among whom 20/113 (17.7%) had multiple mutations and 59 (52%) were clinically silent. Variant allele frequency (VAF) varied from 0.3% to 89%. VAF positively correlated (P < .0001) with the percent blasts, leukocytes, dyserythropoiesis and dysmegakaryopoiesis scores, and clinical disease severity, and negatively with hemoglobin, although only 4/113 were anemic. GATA1s mutations were detected from 28 weeks gestation; the highest frequency (45%) was at 34 to 35 weeks, whereas mutation frequency in early fetal samples (<20 weeks) was <4% (2/57). GATA1s clones (VAF, percent blasts) fell rapidly postnatally, becoming undetectable by 6 months, except in neonates who developed ML-DS. Of 110 surviving neonates, 7 (6.4%) developed ML-DS at a median age of 17.5 months. GATA1s clone size at birth was the only predictor of ML-DS. No neonates lacking GATA1s mutations acquired mutations after birth or developed ML-DS. Taken together, the fetal environment is essential for GATA1s mutation selection and expansion of GATA1s clones. Rates of leukemic transformation of GATA1s clones detected at birth are low, but clones that persist >6 months transformed.

1.
Hasle
H
,
Clemmensen
IH
,
Mikkelsen
M
.
Risks of leukaemia and solid tumours in individuals with Down’s syndrome
.
Lancet
.
2000
;
355
(
9199
):
165
-
169
.
2.
Hasle
H
,
Friedman
JM
,
Olsen
JH
,
Rasmussen
SA
.
Low risk of solid tumors in persons with Down syndrome
.
Genet Med
.
2016
;
18
(
11
):
1151
-
1157
.
3.
Marlow
EC
,
Ducore
J
,
Kwan
ML
, et al
.
Leukemia risk in a cohort of 3.9 million children with and without Down syndrome
.
J Pediatr
.
2021
;
234
:
172
-
180.e3
.
4.
Khoury
J
,
Solary
E
,
Abla
O
, et al
.
The 5th edition of the World Health Organization classification of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms
.
Leukemia
.
2022
;
36
(
7
):
1703
-
1719
.
5.
Zipursky
A
.
Transient leukaemia – a benign form of leukaemia in newborn infants with trisomy 21
.
Br J Haematol
.
2003
;
120
(
6
):
930
-
938
.
6.
Klusmann
JH
,
Creutzig
U
,
Zimmermann
M
, et al
.
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
.
Blood
.
2008
;
111
(
6
):
2991
-
2998
.
7.
Gamis
AS
,
Alonzo
TA
,
Gerbing
RB
, et al
.
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971
.
Blood
.
2011
;
118
(
26
):
6752
-
6996
.
8.
Roberts
I
,
Alford
K
,
Hall
G
, et al
.
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia
.
Blood
.
2013
;
122
(
24
):
3908
-
3917
.
9.
Wechsler
J
,
Greene
M
,
McDevitt
MA
, et al
.
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
.
Nat Genet
.
2002
;
32
(
1
):
148
-
152
.
10.
Mundschau
G
,
Gurbuxani
S
,
Gamis
AS
,
Greene
ME
,
Arceci
RJ
,
Crispino
JD
.
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis
.
Blood
.
2003
;
101
(
11
):
4298
-
4300
.
11.
Hitzler
JK
,
Cheung
J
,
Li
Y
,
Scherer
SW
,
Zipursky
A
.
GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome
.
Blood
.
2003
;
101
(
11
):
4301
-
4304
.
12.
Rainis
L
,
Bercovich
D
,
Strehl
S
, et al
.
Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21
.
Blood
.
2003
;
102
(
3
):
981
-
986
.
13.
Xu
G
,
Nagano
M
,
Kanezaki
R
, et al
.
Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome
.
Blood
.
2003
;
102
(
8
):
2960
-
2968
.
14.
Groet
J
,
McElwaine
S
,
Spinelli
M
, et al
.
Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder
.
Lancet
.
2003
;
361
(
9369
):
1617
-
1620
.
15.
Ahmed
M
,
Sternberg
A
,
Hall
G
, et al
.
Natural history of GATA1 mutations in Down syndrome
.
Blood
.
2004
;
103
(
7
):
2480
-
2489
.
16.
Yoshida
K
,
Toki
T
,
Okuno
Y
, et al
.
The landscape of somatic mutations in Down syndrome-related myeloid disorders
.
Nat Genet
.
2013
;
45
(
11
):
1293
-
1299
.
17.
Labuhn
M
,
Perkins
K
,
Matzk
S
, et al
.
Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with down syndrome
.
Cancer Cell
.
2019
;
36
(
2
):
123
. 138.e10.
18.
Sato
T
,
Yoshida
K
,
Toki
T
, et al
.
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms
.
Blood
.
2024
;
143
(
25
):
2627
-
2643
.
19.
Hollanda
LM
,
Lima
CS
,
Cunha
AF
, et al
.
An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis
.
Nat Genet
.
2006
;
38
(
7
):
807
-
812
.
20.
Koboldt
DC
,
Chen
K
,
Wylie
T
, et al
.
VarScan: variant detection in massively parallel sequencing of individual and pooled samples
.
Bioinformatics
.
2009
;
25
(
17
):
2283
-
2285
.
21.
Maroz
A
,
Stachorski
L
,
Emmrich
S
, et al
.
GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia
.
Leukemia
.
2014
;
28
(
6
):
1259
-
1270
.
22.
Li
Z
,
Godinho
FJ
,
Klusmann
JH
,
Garriga-Canut
M
,
Yu
C
,
Orkin
SH
.
Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1
.
Nat Genet
.
2005
;
37
(
6
):
613
-
619
.
23.
Sankaran
VG
,
Ghazvinian
R
,
Do
R
, et al
.
Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia
.
J Clin Invest
.
2012
;
122
(
7
):
2439
-
2443
.
24.
Birger
Y
,
Goldberg
L
,
Chlon
TM
, et al
.
Perturbation of fetal hematopoiesis in a mouse model of Down syndrome’s transient myeloproliferative disorder
.
Blood
.
2013
;
122
(
6
):
988
-
998
.
25.
Byrska-Bishop
M
,
VanDorn
D
,
Campbell
AE
, et al
.
Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus
.
J Clin Invest
.
2015
;
125
(
3
):
993
-
1005
.
26.
Chlon
TM
,
McNulty
M
,
Goldenson
B
,
Rosinski
A
,
Crispino
JD
.
Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression
.
Haematologica
.
2015
;
100
(
5
):
575
-
584
.
27.
Banno
K
,
Omori
S
,
Hirata
K
, et al
.
Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities
.
Cell Rep
.
2016
;
15
(
6
):
1228
-
1241
.
28.
Ling
T
,
Birger
Y
,
Stankiewicz
MJ
, et al
.
Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis
.
Blood
.
2019
;
134
(
19
):
1619
-
1631
.
29.
Juban
G
,
Sakakini
N
,
Chagraoui
H
, et al
.
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay
.
Haematologica
.
2021
;
106
(
4
):
1106
-
1119
.
30.
Cabelof
DC
,
Patel
HV
,
Chen
Q
, et al
.
Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome
.
Blood
.
2009
;
114
(
13
):
2753
-
2763
.
31.
Alford
KA
,
Reinhardt
K
,
Garnett
C
, et al
.
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia
.
Blood
.
2011
;
118
(
8
):
2222
-
2238
.
32.
Hasaart
KAL
,
Bertrums
EJM
,
Manders
F
,
Goemans
BF
,
van Boxtel
R
.
Increased risk of leukaemia in children with Down syndrome- a somatic evolutionary view
.
Expert Rev Mol Med
.
2021
;
23
:
e5
.
33.
Kanezaki
R
,
Toki
T
,
Terui
K
, et al
.
Down syndrome and GATA1 mutations in transient myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia
.
Blood
.
2010
;
116
(
22
):
4631
-
4638
.
34.
Tamblyn
JA
,
Norton
A
,
Spurgeon
L
, et al
.
Prenatal therapy in transient abnormal myelopoiesis: a systematic review
.
Arch Dis Child Fetal Neonatal Ed
.
2016
;
101
(
1
):
67
-
71
.
35.
Yamato
G
,
Deguchi
T
,
Terui
K
, et al
.
Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome
.
Leukemia
.
2021
;
35
(
5
):
1480
-
1484
.
36.
Flasinski
M
,
Scheibke
K
,
Zimmermann
M
, et al
.
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD prevention 2007 study
.
Blood Adv
.
2018
;
2
(
13
):
1532
-
1540
.
37.
Al-Kershi
S
,
Golnik
R
,
Flasinski
M
, et al
.
Recommendations for the diagnosis and treatment of children with transient abnormal myelopoiesis (TAM) and myeloid leukemia in Down syndrome (ML-DS)
.
Klin Padiatr
.
2021
;
233
(
6
):
267
-
277
.
38.
Bull
MJ
,
Trotter
T
,
Santoro
SL
, et al
.
Health supervision for children and adolescents with Down syndrome
.
Pediatrics
.
2022
;
149
(
5
):
e2022057010
.
39.
Wagenblast
E
,
Araújo
J
,
Gan
OI
, et al
.
Mapping the cellular origin and early evolution of leukemia in Down syndrome
.
Science
.
2021
;
373
(
6551
):
eabf6202
.
40.
Cruz Hernandez
D
,
Metzner
M
,
de Groot
A
, et al
.
Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome
.
Blood
.
2020
;
136
(
12
):
1460
-
1465
.
41.
Goemans
BF
,
Noort
S
,
Blink
M
, et al
.
Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia
.
Leukemia
.
2021
;
35
(
8
):
2403
-
2406
.
42.
Mizuta
S
,
Yamane
N
,
Mononobe
S
, et al
.
Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome
.
Int J Lab Hematol
.
2022
;
44
(
2
):
349
-
355
.
43.
Tunstall
O
,
Bhatnagar
N
,
James
B
, et al
.
Guidelines for the investigation and management of transient leukaemia of Down syndrome
.
Br J Haematol
.
2018
;
182
(
2
):
200
-
211
.
44.
Marderstein
AR
,
De Zuani
M
,
Moeller
R
, et al
.
Single-cell multi-omics map of human fetal blood in Down syndrome
.
Nature
.
2024
;
634
(
8032
):
104
-
112
.
45.
Hasaart
KAL
,
Manders
F
,
van der Hoorn
ML
, et al
.
Mutation accumulation and developmental lineages in normal and Down syndrome human fetal hematopoiesis
.
Sci Rep
.
2020
;
10
(
1
):
12991
.
46.
Chen
CC
,
Silberman
RE
,
Ma
D
, et al
.
Inherent genome instability underlies trisomy 21-associated myeloid malignancies
.
Leukemia
.
2024
;
38
(
3
):
521
-
529
.
47.
Li
Y
,
Elliott
N
,
Lein
P
,
Vyas
P
,
Roberts
I
,
de Smith
AJ
.
Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome
.
Blood Adv
.
2025
;
9
(
16
):
4235
-
4243
.
You do not currently have access to this content.
Sign in via your Institution